4.6 Article

Dipeptidyl peptidase IV inhibitors and the risk of mycobacterial pulmonary infections in type 2 diabetes mellitus

Related references

Note: Only part of the references are listed.
Article Immunology

Completion Rate and Safety of Programmatic Screening and Treatment for Latent Tuberculosis Infection in Elderly Patients With Poorly Controlled Diabetic Mellitus: A Prospective Multicenter Study

Hung-Ling Huang et al.

Summary: The study found that the prevalence of latent tuberculosis infection was over 25% in elderly patients with poorly controlled diabetes mellitus under the care of a collaborative multidisciplinary team. Despite a high completion rate of preventive therapy, some patients still experienced adverse drug reactions.

CLINICAL INFECTIOUS DISEASES (2021)

Review Pharmacology & Pharmacy

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence

Tianli Zhang et al.

Summary: DPP4 is a type II transmembrane glycoprotein widely expressed in various organs and cells, with roles in energy metabolism, inflammation, and immune function. Approved by FDA for treating type 2 diabetes, it is also implicated in lung diseases and may play a significant role in COVID-19, making it a potential therapeutic target and biomarker.

FRONTIERS IN PHARMACOLOGY (2021)

Review Endocrinology & Metabolism

Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus

Carolyn F. Deacon

NATURE REVIEWS ENDOCRINOLOGY (2020)

Review Endocrinology & Metabolism

Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes

Carolyn F. Deacon

FRONTIERS IN ENDOCRINOLOGY (2019)

Article Respiratory System

The risk of mycobacterial infections associated with inhaled corticosteroid use

Sarah K. Brode et al.

EUROPEAN RESPIRATORY JOURNAL (2017)

Article Medicine, General & Internal

Short-term dipeptidyl peptidase-4 inhibitor use increases the risk of herpes zoster infection in Asian patients with diabetes

H. -H. Chen et al.

QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2016)

Article Microbiology

Diabetes and Tuberculosis

Blanca I. Restrepo

MICROBIOLOGY SPECTRUM (2016)

Article Multidisciplinary Sciences

Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study

Rogier Wvan Der Zanden et al.

PLOS ONE (2015)

Article Medicine, Research & Experimental

Global Epidemiology of Tuberculosis

Philippe Glaziou et al.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2015)

Review Endocrinology & Metabolism

The New insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes

Yunjuan Zhao et al.

DIABETES-METABOLISM RESEARCH AND REVIEWS (2014)

Review Immunology

CD4+ T-cell subsets and host defense in the lung

Jay K. Kolls

IMMUNOLOGICAL REVIEWS (2013)

Article Medicine, General & Internal

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Benjamin M. Scirica et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Review Immunology

Host defenses against bacterial lower respiratory tract infection

Taylor Eddens et al.

CURRENT OPINION IN IMMUNOLOGY (2012)

Editorial Material Endocrinology & Metabolism

Mechanism of Action of DPP-4 Inhibitors-New Insights

Adrian Vella

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)

Article Mathematics, Interdisciplinary Applications

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

Peter C. Austin

MULTIVARIATE BEHAVIORAL RESEARCH (2011)

Article Urology & Nephrology

Survival analysis: time-dependent effects and time-varying risk factors

Friedo W. Dekker et al.

KIDNEY INTERNATIONAL (2008)

Review Critical Care Medicine

An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases

David E. Griffith et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)